Colorectal Cancer Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Therapy (Adjuvant Chemotherapy, Palliative Chemotherapy, Immuno Therapy, Neo Adjuvant Chemotherapy), By Drug Type (Capecitabine, Irinotecan, Fluorouracil, Trifluridine/tipiracil, Oxaliplatin, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) and Region Forecast 2020-2031

Colorectal Cancer Drugs Market size was valued at 15.5 billion in 2023 and is expected to reach 23.0 billion by 2030, at a significant CAGR of 8.5% from 2024-2030. Colorectal cancer is also known as bowel cancer. It refers to the abnormal growth of the cells in colon and rectum due to cancer. Colorectal cancer starts either in the colon and rectum. Cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain.

Colorectal cancer is the third most common cancer in the world. Huge government initiatives taken by the nations are booming up the growth of the colorectal cancer drugs treatment market globally. Biologics such as Zaltrap (Ziv-Aflibercept), Erbitux (Cetuximab), Avastin (Bevacizumab) are using rapidly for the treatment for colorectal cancer that are used as a targeted therapy and they acts only on the malignant cells. Market players in the market forming strategic alliances and partnerships to increase their market share.

Key Developments:

On January 16, 2025: The Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

On 8 November, 2023: Takeda has announced that the U.S. FDA has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have undergone prior treatments, including chemotherapy and specific targeted therapies. This approval makes FRUZAQLA the first selective inhibitor of all three VEGF receptor kinases in the U.S. for previously treated mCRC patients, irrespective of biomarker status. Notably, this approval came under Priority Review, ahead of the scheduled PDUFA date. FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status or Prior Types of Therapies in More Than a Decade